Evidence map›Paper›PMID 29180759›Full record

ArticleNature communications2017

Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression.

Jianqin Lu, Xiangsheng Liu, Yu-Pei Liao, Felix Salazar, Bingbing Sun, Wen Jiang, Chong Hyun Chang, Jinhong Jiang, Xiang Wang, Anna M Wu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 183 papers.

0numbers the graph read from it
0cells of the map it votes in
183citing papers in PubMed
18.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

183 citing papers in PubMed, 434 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

123 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jianqin LuDivision of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0002-5877-619X
Xiangsheng LiuDivision of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Yu-Pei LiaoDivision of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Felix SalazarDepartment of Molecular and Medical Pharmacology Crump Institute for Molecular Imaging, David Geffen School of Medicine, Los Angeles, CA, 90095, USA.
Bingbing SunDivision of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0002-5444-5078
Wen JiangCenter for Environmental Implications of Nanotechnology, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.ORCID http://orcid.org/0000-0002-5775-9523
Chong Hyun ChangCenter for Environmental Implications of Nanotechnology, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Jinhong JiangCenter for Environmental Implications of Nanotechnology, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Xiang WangCenter for Environmental Implications of Nanotechnology, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Anna M WuDepartment of Molecular and Medical Pharmacology Crump Institute for Molecular Imaging, David Geffen School of Medicine, Los Angeles, CA, 90095, USA.
Huan MengDivision of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA. hmeng@mednet.ucla.edu.
Andre E NelDivision of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA. anel@mednet.ucla.edu.
California NanoSystems Institute · USInstitute for Molecular Medicine · USUniversity of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas CancerU01CA198846 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, MENG, HUAN · 2015 to 2019
$2.4M
(PQC4) Imaging CD8 T Cells In Tumor Immunotherapy By ImmunopetR21CA190044 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, ANNA M · 2014 to 2015
$368k
NCI NIH HHS P30 CA016042NCI NIH HHS R21 CA190044NCI NIH HHS U01 CA198846
6 · The paper itself

Abstract

While chemotherapy delivery by nanocarriers has modestly improved the survival prospects of pancreatic ductal adenocarcinoma (PDAC), additional engagement of the immune response could be game changing. We demonstrate a nano-enabled approach for accomplishing robust anti-PDAC immunity in syngeneic mice through the induction of immunogenic cell death (ICD) as well as interfering in the immunosuppressive indoleamine 2,3-dioxygenase (IDO) pathway. This is accomplished by conjugating the IDO inhibitor, indoximod (IND), to a phospholipid that allows prodrug self-assembly into nanovesicles or incorporation into a lipid bilayer that encapsulates mesoporous silica nanoparticles (MSNP). The porous MSNP interior allows contemporaneous delivery of the ICD-inducing chemotherapeutic agent, oxaliplatin (OX). The nanovesicles plus free OX or OX/IND-MSNP induce effective innate and adaptive anti-PDAC immunity when used in a vaccination approach, direct tumor injection or intravenous biodistribution to an orthotopic PDAC site. Significant tumor reduction or eradication is accomplishable by recruiting cytotoxic T lymphocytes, concomitant with downregulation of Foxp3

Indexed as

Adaptive ImmunityAnimalsAntineoplastic AgentsApoptosisCarcinoma, Pancreatic DuctalCell Line, TumorDrug CarriersFeasibility StudiesFemaleForkhead Transcription FactorsHumansImmune ToleranceImmunity, InnateImmunotherapyIndoleamine-Pyrrole 2,3,-DioxygenaseMale1-methyltryptophanAntineoplastic AgentsDrug CarriersForkhead Transcription FactorsFoxp3 protein, mouseIDO1 protein, mouseIndoleamine-Pyrrole 2,3,-DioxygenaseOrganoplatinum CompoundsOxaliplatinPhospholipidsProdrugsSilicon DioxideTryptophan

Identifiers

PMID29180759
PMCPMC5703845
OpenAlexW2770810616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.